

# Henrik Schmidt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4341310/publications.pdf>

Version: 2024-02-01

50  
papers

9,841  
citations

257357

24  
h-index

223716

46  
g-index

50  
all docs

50  
docs citations

50  
times ranked

14170  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation. <i>New England Journal of Medicine</i> , 2015, 372, 320-330.	13.9	4,795
2	Tertiary lymphoid structures improve immunotherapy and survival in melanoma. <i>Nature</i> , 2020, 577, 561-565.	13.7	1,209
3	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC Tj ETQq1 1 0,784314 rgBT /Overall survival). <i>Journal of Clinical Oncology</i> , 2017, 35, 1093-1103.	5.1	1,093
4	A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. <i>Journal of Translational Medicine</i> , 2011, 9, 204.	1.8	500
5	Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. <i>Clinical Cancer Research</i> , 2017, 23, 1929-1936.	3.2	290
6	Dabrafenib, trametinib and pembrolizumab or placebo in <i>BRAF</i> -mutant melanoma. <i>Nature Medicine</i> , 2019, 25, 941-946.	15.2	256
7	Pretreatment Levels of Peripheral Neutrophils and Leukocytes As Independent Predictors of Overall Survival in Patients With American Joint Committee on Cancer Stage IV Melanoma: Results of the EORTC 18951 Biochemotherapy Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 1562-1569.	0.8	171
8	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 119, 1-10.	1.3	132
9	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2017, 3, 1511.	3.4	131
10	Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3937-3946.	0.8	119
11	Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. <i>Cancer</i> , 2006, 106, 1130-1139.	2.0	118
12	KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i> -mutant melanoma. , 2020, 8, e001806.		110
13	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 393-403.	5.1	91
14	The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials. <i>European Journal of Cancer</i> , 2017, 74, 89-95.	1.3	77
15	Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. <i>Oncolimmunology</i> , 2016, 5, e1100788.	2.1	73
16	Serum YKL-40 Predicts Relapse-Free and Overall Survival in Patients With American Joint Committee on Cancer Stage I and II Melanoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 798-804.	0.8	71
17	Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients. , 2018, 6, 152.		53
18	The impact of patient involvement in research: a case study of the planning, conduct and dissemination of a clinical, controlled trial. <i>Research Involvement and Engagement</i> , 2020, 6, 43.	1.1	48

#	ARTICLE	IF	CITATIONS
19	Safety and Clinical Effect of Subcutaneous Human Interleukin-21 in Patients with Metastatic Melanoma or Renal Cell Carcinoma: A Phase I Trial. <i>Clinical Cancer Research</i> , 2010, 16, 5312-5319.	3.2	47
20	The real-world impact of modern treatments on the survival of patients with metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 108, 25-32.	1.3	47
21	Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFN $\gamma$ Signaling. <i>Cancer Research</i> , 2017, 77, 4562-4566.	0.4	39
22	Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. <i>Cancers</i> , 2019, 11, 1489.	1.7	37
23	Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA9008-LBA9008.	0.8	32
24	Granzyme B Degraded Type IV Collagen Products in Serum Identify Melanoma Patients Responding to Immune Checkpoint Blockade. <i>Cancers</i> , 2020, 12, 2786.	1.7	32
25	Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. <i>Melanoma Research</i> , 2005, 15, 409-416.	0.6	30
26	Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker. <i>Journal of Clinical Pathology</i> , 2014, 67, 520-528.	1.0	30
27	Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 119, 122-131.	1.3	27
28	The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. <i>Cancer Epidemiology</i> , 2021, 73, 101943.	0.8	21
29	Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2512-2512.	0.8	18
30	Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9605-TPS9605.	0.8	16
31	Severe steroid refractory gastritis induced by Nivolumab: A case report. <i>World Journal of Gastroenterology</i> , 2020, 26, 1971-1978.	1.4	15
32	Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA9008-LBA9008.	0.8	14
33	Automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma. <i>Diagnostic Pathology</i> , 2016, 11, 35.	0.9	11
34	High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort. <i>European Journal of Cancer</i> , 2019, 115, 61-67.	1.3	11
35	The real-world outcome of metastatic melanoma: Unknown primary vs known cutaneous. <i>International Journal of Cancer</i> , 2019, 145, 3173-3174.	2.3	9
36	Effect of patient-reported outcomes as a dialogue-based tool in cancer consultations on patient self-management and health-related quality of life: a clinical, controlled trial. <i>Acta Oncologica</i> , 2021, 60, 1668-1677.	0.8	9

#	ARTICLE	IF	CITATIONS
37	S100 <sup>β</sup> protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma. <i>Melanoma Research</i> , 2004, 14, 211-215.	0.6	8
38	Circulating Tyrosinase and MART-1 mRNA does not Independently Predict Relapse or Survival in Patients with AJCC Stage Iâ€”II Melanoma. <i>Journal of Investigative Dermatology</i> , 2006, 126, 849-854.	0.3	8
39	Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma. <i>Cancers</i> , 2020, 12, 2591.	1.7	8
40	Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in <i>BRAF</i><sup>V600E/K</sup>-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9516-9516.	0.8	6
41	EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600â€”mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF/MEK inhibition.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9540-9540.	0.8	5
42	Genetic predisposition to long telomeres is associated with increased mortality after melanoma: A study of 2101 melanoma patients from hospital clinics and the general population. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 946-954.	1.5	4
43	A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS9106-TPS9106.	0.8	4
44	Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9539-9539.	0.8	4
45	Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study. <i>Cancers</i> , 2021, 13, 5550.	1.7	4
46	Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2022, 24, 43.	1.6	4
47	Measured and genetically predicted plasma YKL-40 levels and melanoma mortality. <i>European Journal of Cancer</i> , 2019, 121, 74-84.	1.3	3
48	A case report: metastasis of melanoma to the heart in an era of immunotherapy. <i>European Heart Journal - Case Reports</i> , 2019, 3, 1-7.	0.3	1
49	Serum IL-6 as a prognostic biomarker in patients with stage IIB-III melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8545-8545.	0.8	0
50	Assessment of extracellular matrix and tissue derived metabolites in a liquid biopsy for identifying endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14050-e14050.	0.8	0